Abstract
Introduction
Methamphetamine (MA) use disorder is an important public health concern. MA withdrawal is often the first step in ceasing or reducing use. There are no evidence-based withdrawal treatments, and no medication is approved for the treatment of MA withdrawal. Lisdexamfetamine (LDX) dimesilate, used in the treatment of attention deficit hyperactivity disorder and binge eating disorder has the potential as an agonist therapy to ameliorate withdrawal symptoms, and improve outcomes for patients.
Methods
A single arm, open-label pilot study to test the safety and feasibility of LDX for the treatment of MA withdrawal. Participants will be inpatients in a drug and alcohol withdrawal unit, and will receive a tapering dose of LDX over five days: 250mg LDX on Day 1, reducing by 50mg per day to 50mg on Day 5. Optional inpatient Days 6 and 7 will allow for participants to transition to ongoing treatment. Participants will be followed-up on Days 14, 21 and 28. All participants will also receive standard inpatient withdrawal care. The primary outcomes are safety (measured by adverse events, changes in vital signs, changes in suicidality and psychosis) and feasibility (the time taken to enrol the sample, proportion of screen / pre-screen failures). Secondary outcomes are acceptability (treatment satisfaction questionnaire, medication adherence, concomitant medications, qualitative interviews), retention to protocol (proportion retained to primary and secondary endpoints), changes in withdrawal symptoms (Amphetamine Withdrawal Questionnaire) and craving for MA (visual analogue scale), and sleep outcomes (continuous actigraphy and daily sleep diary).
Discussion
This is the first study to assess lisdexamfetamine for the treatment of acute MA withdrawal. If safe and feasible results will go to informing the development of multi-centre randomised controlled trials to determine the efficacy of the intervention.
Funder
The National Center for Clinical Research on Emerging Drugs
Publisher
Public Library of Science (PLoS)
Reference61 articles.
1. McKetin R, McLaren J, Kelly E, McKetin R. The Sydney methamphetamine market: Patterns of supply, use, personal harms and social consquences: National Drug Law Enforcement Research Fund; 2005.
2. United Nations. World Drug Report. 2019. Contract No.: E.19.XI.9.
3. Responding to global stimulant use: challenges and opportunities;M Farrell;Lancet,2019
4. Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia;J Hando;Drug Alcohol Depend,1997
5. A comparison of the harms associated with the injection of heroin and amphetamines;S Kaye;Drug Alcohol Depend,2000
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献